隨著時間的推進，許多具有專利的大分子蛋白藥物紛紛到期，因此有越來越多廠商投入開發生物相似藥。生物相似藥除了可以提供更多的治療選擇外，透過競爭也可以降低醫療的成本，近年也成為生技產業發展的一個趨勢。
在研究的領域中，亞旭所代理的Ichorbio能以最快的速度提供生物相似藥，並在2022年開始提供超過一百多種的cGMP等級的研究生物相似藥，能成為您實驗最堅強的後盾
優惠產品列表:
Cat Number | Name | Target |
ICH4001 | Adalimumab Biosimilar | TNF Alpha |
ICH4002 | Alemtuzumab Biosimilar | CD52 |
ICH4003 | Bevacizumab Biosimilar | VEGF |
ICH4004 | Cetuximab Biosimilar | EGFR |
ICH4005 | Eculizumab Biosimilar | C5 |
ICH4006 | Infliximab Biosimilar | TNF Alpha |
ICH4008 | Nimotuzumab Biosimilar | EGFR |
ICH4009 | Nivolumab Biosimilar | PD-1 |
ICH4010 | Omalizumab Biosimilar | IGE |
ICH4011 | Rituximab Biosimilar | CD20 |
ICH4012 | Tocilizumab Biosimilar | IL6R |
ICH4013 | Trastuzumab Biosimilar | ERBB2 |
ICH4014 | Ado-trastuzumab emtansine Biosimilar | ERBB2 |
ICH4015 | Aflibercept Biosimilar | VEGF |
ICH4016 | Alirocumab Biosimilar | PCSK9 |
ICH4017 | Avelumab Biosimilar | PD-L1 |
ICH4018 | Atezolizumab Biosimilar | PD-L1 |
ICH4019 | Denosumab Biosimilar | RANKL |
ICH4020 | Daratumumab Biosimilar | CD38 |
ICH4022 | Etanercept Biosimilar | TNF |
ICH4023 | Evolocumab Biosimilar | PCSK9 |
ICH4025 | Ipilimumab Biosimilar | CTLA-4 |
ICH4026 | Obinutuzumab Biosimilar | CD20 |
ICH4027 | Ofatumumab Biosimilar | CD20 |
ICH4028 | Panitumumab Biosimilar | EGFR |
ICH4029 | Pembrolizumab Biosimilar | PD-1 |
ICH4030 | Pertuzumab Biosimilar | ERBB2 |
ICH4031 | Ranibizumab Biosimilar | VEGF-A |
ICH4032 | Ramucirumab Biosimilar | VEGFR2 |
Cat Number | Name | Target |
ICH4033 | Secukinumab Biosimilar | IL17A |
ICH4034 | Ustekinumab Biosimilar | IL12/IL23 |
ICH4035 | Vedolizumab Biosimilar | ITGA4B7 |
ICH4036 | Mepolizumab Biosimilar | IL-5 |
ICH4037 | Natalizumab Biosimilar | IL-5 |
ICH5001 | Sintilimab Biosimilar | PD-1 |
ICH5002 | Toripalimab Biosimilar | PD-1 |
ICH5003 | Camrelizumab Biosimilar | PD-1 |
ICH5004 | Tislelizumab Biosimilar | PD-1 |
ICH5005 | Durvalumab Biosimilar | PD-L1 |
ICH5006 | M7824 Biosimilar | PD-L1 & TGF-B |
ICH5007 | Naptumomab Biosimilar | 5T4 |
ICH5008 | Aducanumab Biosimilar | Amyloid Beta |
ICH5009 | Gantenerumab Biosimilar | Amyloid Beta |
ICH5010 | Nesvacumab Biosimilar | ANG2 |
ICH5011 | Belantamab mafodotin Biosimilar | BCMA |
ICH5012 | Sutimlimab Biosimilar | C1S |
ICH5013 | Girentuximab Biosimilar | CAIX |
ICH5014 | Utomilumab Biosimilar | 4-1BB |
ICH5015 | Urelumab Biosimilar | 4-1BB |
ICH5016 | Atibuclimab Biosimilar | CD14 |
ICH5017 | Monalizumab Biosimilar | NKG2A |
ICH5018 | MDX-1342 Biosimilar | CD19 |
ICH5019 | Glofitamab Biosimilar | CD3/CD20 |
ICH5020 | Moxetumomab pasudotox Biosimilar | CD22 |
ICH5021 | Daclizumab Biosimilar | CD25 |
ICH5022 | Varlilumab Biosimilar | CD27 |
ICH5023 | Theralizumab Biosimilar | CD28 |
ICH5024 | Muromonab-CD3 Biosimilar | CD3E |
Cat Number | Name | Target |
ICH5025 | Blinatumomab Biosimilar | CD3/CD19 |
ICH5026 | Mosunetuzumab Biosimilar | CD3/CD20 |
ICH5027 | Odronextamab Biosimilar | CD3/CD20 |
ICH5028 | Isatuximab Biosimilar | CD38 |
ICH5029 | Ibalizumab Biosimilar | CD4 |
ICH5030 | Dacetuzumab Biosimilar | CD40 |
ICH5031 | Sotigalimab Biosimilar | CD40 |
ICH5032 | Selicrelumab Biosimilar | CD40 |
ICH5033 | SRF231 Biosimilar | CD47 |
ICH5034 | Lemzoparlimab Biosimilar | CD47 |
ICH5035 | CC-90002 Biosimilar | CD47 |
ICH5036 | Magrolimab Biosimilar | CD47 |
ICH5037 | Cusatuzumab Biosimilar | CD70 |
ICH5038 | Oleclumab Biosimilar | CD73 |
ICH5039 | Polatuzumab vedotin Biosimilar | CD79B |
ICH5040 | Tusamitamab Biosimilar | CEACAM5 |
ICH5041 | Cibisatamab Biosimilar | CEA/CD3 |
ICH5042 | Tinurilimab Biosimilar | CEACAM6 |
ICH5043 | Erenumab Biosimilar | CGRP receptor |
ICH5044 | Eptinezumab Biosimilar | CALCA/CALCB |
ICH5045 | Fremanezumab Biosimilar | CGRP |
ICH5046 | Galcanezumab Biosimilar | CGRP |
ICH5047 | Zolbetuximab Biosimilar | Claudin 18.2 |
ICH5048 | Rovalpituzumab Biosimilar | DLL3 |
ICH5049 | Batoclimab Biosimilar | FCRN |
ICH5050 | Nipocalimab Biosimilar | FCRN |
ICH5051 | Rozanolixizumab Biosimilar | FCRN |
ICH5052 | Aprutumab Biosimilar | FGFR |
ICH5053 | Bemarituzumab Biosimilar | FGFR2B |
Cat Number | Name | Target |
ICH5054 | Mavrilimumab Biosimilar | GMCSF |
ICH5055 | Codrituzumab Biosimilar | GPC3 |
ICH5056 | Abciximab Biosimilar | GPIIB/GPIIIA |
ICH5058 | Lebrikizumab Biosimilar | IL-13 |
ICH5059 | Tralokinumab Biosimilar | IL-13 |
ICH5061 | Etokimab Biosimilar | IL-33 |
ICH5063 | Clazakizumab Biosimilar | IL-6 |
ICH5064 | Guselkumab Biosimilar | IL-23 |
ICH5065 | BMS986016 Biosimilar | LAG3 |
ICH5067 | TSR-033 Biosimilar | LAG3 |
ICH5068 | Simtuzumab Biosimilar | LOXL2 |
ICH5069 | Amatuximab Biosimilar | MSLN |
ICH5070 | Enfortumab vedotin Biosimilar | NECTIN-4 |
ICH5071 | Palivizumab Biosimilar | RSV-F |
ICH5072 | 5G12 Biosimilar | SIGLEC15 |
ICH5074 | KWAR23 Biosimilar | SIRP ALPHA |
ICH5075 | Elotuzumab Biosimilar | SLAMF7 |
ICH5076 | Sacituzumab Biosimilar | TACSTD2 |
ICH5077 | Fresolimumab Biosimilar | TGFBETA1 |
ICH5078 | Tiragolumab Biosimilar | TIGIT |
ICH5079 | Sabatolimab Biosimilar | TIM3 |
ICH5080 | Belimumab Biosimilar | TNFSF13B |
ICH5081 | Onvatilimab Biosimilar | VISTA |
ICH5082 | Caplacizumab Biosimilar | VWF |
